<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35312194</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1096-8652</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>97</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>American journal of hematology</Title>
          <ISOAbbreviation>Am J Hematol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Registry data analysis of hematopoietic stem cell transplantation on systemic chronic active Epstein-Barr virus infection patients in Japan.</ArticleTitle>
        <Pagination>
          <StartPage>780</StartPage>
          <EndPage>790</EndPage>
          <MedlinePgn>780-790</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/ajh.26544</ELocationID>
        <Abstract>
          <AbstractText>The effects of allogeneic hematopoietic stem cell transplantation (allo-HSCT) on systemic chronic active Epstein-Barr virus infection (sCAEBV) are yet to be analyzed in a large number of patients. Using the Japanese registry database, Transplant Registry Unification Management Program, we investigated the outcomes of 102 sCAEBV patients who underwent allo-HSCT. The median age at HSCT was 21 years, and the three-year overall survival (3-year OS) rate was 72.5%. Of the 90 patients whose viral load after allo-HSCT was evaluated, 56 (62.2%) achieved a virological complete response, defined by the complete resolution of disease activity with a significant decrease in EBV-DNA in peripheral blood. The multivariate Cox proportional hazard model indicated that advanced age, in adolescents and young adults (AYA) (age, 15-39) and adults (age, ≥40 years) was a risk factor of poor OS. The hazard ratios (HRs) of the AYA and adult groups were 10.87 (95% confidence interval [CI]: 1.98-59.56, p = .006) and 15.93 (95% CI: 2.45-103.8, p = .004), respectively. Disease activity (HR 5.74), elevated soluble IL-2 receptor (sIL-2R) (≥ median, 691 U/mL) at HSCT (HR 6.93), and conditioning without radiotherapy (HR 3.53) were also independently associated with poor survival. Notably, 79% of radiotherapy doses were less than 6 Gy. Regardless of the presence of hemophagocytic lymphohistiocytosis, the group with a high sIL-2R level (≥2000 U/mL) showed a poorer prognosis. Although allo-HSCT is the only curative therapy for sCAEBV, treatment strategies need to be improved for high-risk patients, especially those with high levels of sIL-2R.</AbstractText>
          <CopyrightInformation>© 2022 Wiley Periodicals LLC.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yamamoto</LastName>
            <ForeName>Masahide</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-3142-8806</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sato</LastName>
            <ForeName>Maho</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology/Oncology, Osaka Women's and Children's Hospital, Izumi, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Onishi</LastName>
            <ForeName>Yasushi</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0003-0032-6994</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, Tohoku University Hospital, Sendai, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sasahara</LastName>
            <ForeName>Yoji</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0003-0030-1535</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Tohoku University Hospital, Sendai, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sano</LastName>
            <ForeName>Hideki</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0002-3242-6917</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pediatric Oncology, Fukushima Medical University Hospital, Fukushima, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Masuko</LastName>
            <ForeName>Masayoshi</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-3760-3089</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Stem Cell Transplantation, Niigata University Medical and Dental Hospital, Niigata, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nakamae</LastName>
            <ForeName>Hirohisa</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0003-4203-990X</Identifier>
            <AffiliationInfo>
              <Affiliation>Hematology, Osaka City University Hospital, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Matsuoka</LastName>
            <ForeName>Ken-Ichi</ForeName>
            <Initials>KI</Initials>
            <Identifier Source="ORCID">0000-0001-7955-8266</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ara</LastName>
            <ForeName>Takahide</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0001-9609-3202</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, Hokkaido University Hospital, Sapporo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Washio</LastName>
            <ForeName>Kana</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0001-6126-0189</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Okayama University Hospital, Okayama, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Onizuka</LastName>
            <ForeName>Makoto</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0003-3864-0823</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Hematology/Oncology, Tokai University School of Medicine, Isehara, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Watanabe</LastName>
            <ForeName>Kenichiro</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0002-8892-3082</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Hematology and Oncology, Shizuoka Children's Hospital, Shizuoka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Takahashi</LastName>
            <ForeName>Yoshiyuki</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0001-8644-171X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hirakawa</LastName>
            <ForeName>Tsuneaki</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology and Oncology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nishio</LastName>
            <ForeName>Miwako</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Laboratory Molecular Genetics of Hematology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sakashita</LastName>
            <ForeName>Chizuko</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kobayashi</LastName>
            <ForeName>Tohru</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0002-7630-5367</Identifier>
            <AffiliationInfo>
              <Affiliation>Clinical Research Center, National Center for Child Health and Development, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sawada</LastName>
            <ForeName>Akihisa</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-7906-8854</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Hematology/Oncology, Osaka Women's and Children's Hospital, Izumi, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ichinohe</LastName>
            <ForeName>Tatsuo</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0002-0393-4066</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Higashihiroshima, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fukuda</LastName>
            <ForeName>Takahiro</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hashii</LastName>
            <ForeName>Yoshiko</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0003-1668-274X</Identifier>
            <AffiliationInfo>
              <Affiliation>Cancer Immunotherapy/Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Atsuta</LastName>
            <ForeName>Yoshiko</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0003-4404-2870</Identifier>
            <AffiliationInfo>
              <Affiliation>Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arai</LastName>
            <ForeName>Ayako</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-8275-5372</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Hematology and Oncology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Hematological Therapeutics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Am J Hematol</MedlineTA>
        <NlmUniqueID>7610369</NlmUniqueID>
        <ISSNLinking>0361-8609</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000078332" MajorTopicYN="N">Data Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020031" MajorTopicYN="Y">Epstein-Barr Virus Infections</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018380" MajorTopicYN="Y">Hematopoietic Stem Cell Transplantation</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004854" MajorTopicYN="N">Herpesvirus 4, Human</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>21</Day>
          <Hour>12</Hour>
          <Minute>19</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35312194</ArticleId>
        <ArticleId IdType="doi">10.1002/ajh.26544</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Straus SE. The chronic mononucleosis syndrome. J Infect Dis. 1988;157(3):405-412.</Citation>
        </Reference>
        <Reference>
          <Citation>Quintanilla-Martinez I, Ko YH, Kimura H, Jaffe ES. EBV-positive T-cell and NK-cell lymphoproliferative diseases of childhood. In: Swerdlow SH, Empo E, Harris NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. International Agency for Research on Cancer; 2017:335-362.</Citation>
        </Reference>
        <Reference>
          <Citation>Kimura H, Ito Y, Kawabe S, et al. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood. 2012;119(3):673-686.</Citation>
        </Reference>
        <Reference>
          <Citation>Kawamoto K, Miyoshi H, Suzuki T, et al. A distinct subtype of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorder: adult patients with chronic active Epstein-Barr virus infection-like features. Haematologica. 2018;103(6):1018-1028.</Citation>
        </Reference>
        <Reference>
          <Citation>Yonese I, Sakashita C, Imadome KI, et al. Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification. Blood Adv. 2020;4(13):2918-2926.</Citation>
        </Reference>
        <Reference>
          <Citation>Kawa K, Sawada A, Sato M, et al. Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection. Bone Marrow Transplant. 2011;46(1):77-83.</Citation>
        </Reference>
        <Reference>
          <Citation>Arai A, Sakashita C, Hirose C, et al. Hematopoietic stem cell transplantation for adults with EBV-positive T- or NK-cell lymphoproliferative disorders: efficacy and predictive markers. Bone Marrow Transplant. 2016;51(6):879-882.</Citation>
        </Reference>
        <Reference>
          <Citation>Atsuta Y, Suzuki R, Yoshimi A, et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP system. Int J Hematol. 2007;86(3):269-274.</Citation>
        </Reference>
        <Reference>
          <Citation>Atsuta Y. Introduction of transplant registry unified management program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol. 2016;103(1):3-10.</Citation>
        </Reference>
        <Reference>
          <Citation>Henter JI, Horne A, Aricó M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131.</Citation>
        </Reference>
        <Reference>
          <Citation>Okano M, Kawa K, Kimura H, et al. Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection. Am J Hematol. 2005;80(1):64-69.</Citation>
        </Reference>
        <Reference>
          <Citation>Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628-1633.</Citation>
        </Reference>
        <Reference>
          <Citation>Giralt S, Ballen K, Rizzo D, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15(3):367-369.</Citation>
        </Reference>
        <Reference>
          <Citation>Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48(3):452-458.</Citation>
        </Reference>
        <Reference>
          <Citation>Umino K, Fujiwara SI, Minakata D, et al. Prognostic impact of serum soluble interleukin-2 receptor level at diagnosis in elderly patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Lymphoma. 2019;60(3):734-741.</Citation>
        </Reference>
        <Reference>
          <Citation>Yamamoto M, Tanaka K, Umezawa Y, Nagao T, Toyota S, Miura O. Soluble interleukin-2 receptor level at diagnosis predicts prognosis of patients with follicular lymphoma irrespective of initial management strategy. Anticancer Res. 2019;39(9):5115-5122.</Citation>
        </Reference>
        <Reference>
          <Citation>Shiratori S, Kosugi-Kanaya M, Shigematsu A, et al. Ultra-high level of serum soluble interleukin-2 receptor at diagnosis predicts poor outcome for angioimmunoblastic T-cell lymphoma. Leuk Lymphoma. 2015;56(9):2592-2597.</Citation>
        </Reference>
        <Reference>
          <Citation>Katsuya H, Shimokawa M, Ishitsuka K, et al. Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma. Blood. 2017;130(1):39-47.</Citation>
        </Reference>
        <Reference>
          <Citation>Coca A, Bundy KW, Marston B, Huggins J, Looney RJ. Macrophage activation syndrome: serological markers and treatment with anti-thymocyte globulin. Clin Immunol. 2009;132(1):10-18.</Citation>
        </Reference>
        <Reference>
          <Citation>Hayden A, Lin M, Park S, et al. Soluble interleukin-2 receptor is a sensitive diagnostic test in adult HLH. Blood Adv. 2017;1(26):2529-2534.</Citation>
        </Reference>
        <Reference>
          <Citation>Imashuku S, Hibi S, Sako M, et al. Soluble interleukin-2 receptor: a useful prognostic factor for patients with hemophagocytic lymphohistiocytosis. Blood. 1995;86(12):4706-4707.</Citation>
        </Reference>
        <Reference>
          <Citation>Lin M, Park S, Hayden A, et al. Clinical utility of soluble interleukin-2 receptor in hemophagocytic syndromes: a systematic scoping review. Ann Hematol. 2017;96(8):1241-1251.</Citation>
        </Reference>
        <Reference>
          <Citation>Zoref-Lorenz A, Murakami J, Hofstetter L, et al. An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis. Blood. 2022;139(7):1098-1110.</Citation>
        </Reference>
        <Reference>
          <Citation>Locatelli F, Jordan MB, Allen C, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med. 2020;382(19):1811-1822.</Citation>
        </Reference>
        <Reference>
          <Citation>Ahmed A, Merrill SA, Alsawah F, et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol. 2019;6(12):e630-e637.</Citation>
        </Reference>
        <Reference>
          <Citation>Goldsmith SR, Saif Ur Rehman S, Shirai CL, Vij K, DiPersio JF. Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib. Blood Adv. 2019;3(23):4131-4135.</Citation>
        </Reference>
        <Reference>
          <Citation>Onozawa E, Shibayama H, Takada H, et al. STAT3 is constitutively activated in chronic active Epstein-Barr virus infection and can be a therapeutic target. Oncotarget. 2018;9(57):31077-31089.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
